UFP Technologies (UFPT) investor relations material

Business overview and strategy

• Focuses on contract development and manufacturing of single-use and single-patient medical devices, with $600M revenue, 5,000+ employees, and 21 manufacturing sites globally.

• Differentiates through exclusive or semi-exclusive access to advanced materials, strong vendor partnerships, and in-house engineering and prototyping.

• Product development is a high-margin, recurring revenue stream, feeding manufacturing and deepening expertise.

• Major business segments: 55% devices, 17% sterile packaging, 28-29% robotic surgery, with fastest growth in largest markets.

• Growth strategy is two-pronged: internal growth by targeting high-value segments and strategic acquisitions aligned with customer needs and technology roadmaps.

Operational highlights and market positioning

• Holds exclusive access to key materials, serving 26 of the top 30 med device companies, and builds custom equipment to increase product stickiness.

• Acquisitions have expanded capabilities and geographic reach, especially in low-cost countries and strategic markets like Ireland and the Dominican Republic.

• Integration approach emphasizes cultural fit and growth synergies, often acquiring companies with strong customer concentration.

• Recent acquisitions (e.g., DAS Medical, AJR) have rapidly scaled revenues and unlocked new business from existing customers.

• Plans to expand into APAC within 12-18 months, co-investing with a major customer.

Financial performance and targets

• Revenue has tripled and medical sales quadrupled in four years, with bottom-line growth of 400%.

• Financial targets: 12-18% revenue growth (half internal, half acquisition), 28-31% gross margins, 17-20% adjusted operating margins.

• One-time labor issue impacted margins but remains within target range; underlying growth trends remain strong.

• Contract extensions with major customers have increased minimums and volumes, supporting further investment in capacity.